Unchanged type 1 metabotropic glutamate receptor availability in patients with Alzheimer's disease: A study using 11C-ITMM positron emission tomography

• Published in: NeuroImage clinical Vol. 22; p. 101783
• Main Authors: Ishibashi, Kenji, Miura, Yoshiharu, Toyohara, Jun, Ishiwata, Kiichi, Ishii, Kenji
• Format: Journal Article
• Language: English
• Published: Elsevier 01.01.2019
• Subjects: Regular
• ISSN: 2213-1582; 2213-1582
• DOI: 10.1016/j.nicl.2019.101783

Imaging of type 1 metabotropic glutamate receptor (mGluR1) has recently become possible using positron emission tomography (PET). To date, little evidence exists on the role of mGluR1 in the pathophysiology of Alzheimer's disease (AD). We aimed to examine mGluR1 availability in patients with AD. Ten patients with AD (78.9 ± 5.9 years) and 12 age-matched volunteers (74.6 ± 2.6 years) underwent PET using an mGluR1 radiotracer. All patients were anti-dementia drug-naive. Volumes-of-interest were placed on the anterior and posterior lobes and vermis in the cerebellum and frontal, parietal, and temporal cortices. The binding potential (BP ND ) was calculated to estimate mGluR1 availability, and partial volume correction was applied to the BP ND values. Mini Mental State Examination (MMSE) scores were also obtained (22.0 ± 4.8). No significant difference was observed in BP ND between the AD and control groups in the anterior lobe (p = .30), posterior lobe (p = .95), vermis (p = .96), frontal cortex (p = .61), parietal cortex (p = .59), or temporal cortex (p = .27). No significant correlation was observed between BP ND and MMSE scores in the anterior lobe (p = .59), posterior lobe (p = .35), vermis (p = .92), frontal cortex (p = .78), parietal cortex (p = .83), or temporal cortex (p = .82). In conclusions, this study suggests that mGluR1 availability is unchanged in the relatively early stage of AD. However, because regional mGluR1 availability may change with the progression of AD, further longitudinal follow-up is necessary. • Metabotropic glutamate receptors (mGluR) can be affected in AD. • Little evidence exists on the role of type 1 mGluR (mGluR1) in AD. • We examined mGluR1 availability in patients with AD. • mGluR1 availability was unchanged in the relatively early stage of AD.